SCOLR Pharma Extends Research Agreement with Consumer Products Company
News Dec 07, 2007
SCOLR Pharma, Inc. has announced an extension of its research agreement with a global consumer products company to co-develop an application of its CDT® drug delivery technology.
Stephen J. Turner, SCOLR’s Vice President and Chief Technical Officer, stated “This extension is a positive indication of the progress we are making with our co-development partner on a novel application of our CDT drug delivery technology. We remain optimistic that if successful, a branded consumer product incorporating our technology could begin commercialization by 2009.”
SCOLR recently announced entering a development and licensing agreement with Dr. Reddy for a cardiopulmonary application of its CDT technology. SCOLR also continues its collaboration with Biocryst to development of an oral application of Biocryst’s peramivir, an anti-viral compound currently in clinical trials as potential intramuscular and intervenous treatments for seasonal and life-threatening influenza.
Under the terms of the agreement, SCOLR will receive a research fee. If the program is successful, it is anticipated that the parties would enter a global license agreement to allow for application of SCOLR’s technology.
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE